{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:32:27Z","timestamp":1792103547708,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Project of Traditional Chinese Medicine Bureau Of Guangdong Province","award":["20231098"],"award-info":[{"award-number":["20231098"]}]},{"name":"the Supporting Scientific Research Funds of the First Affiliated Hospital of Guangzhou University of Chinese Medicine","award":["09005647001"],"award-info":[{"award-number":["09005647001"]}]},{"name":"Guangzhou University of Chinese Medicine's \"Peak Creation\" Project: Promoting the Emergence of Major Achievements","award":["GZY2025ZJ30"],"award-info":[{"award-number":["GZY2025ZJ30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The combination of PD-1\/PD-L1 monoclonal antibodies and chemotherapy has established a new standard of care for the first-line treatment of patients with unresectable locally advanced or metastatic gastric cancer (GC) and gastro-oesophageal junction adenocarcinoma. However, peritoneal metastasis represents a distinct pattern of dissemination in GC, typically associated with a poor prognosis. Whether the combination regimen improves survival for patients with concomitant peritoneal metastasis remains controversial. This study aims to evaluate the efficacy and safety of toripalimab (an anti-PD-1 monoclonal antibody) combined with FLOT chemotherapy as conversion therapy in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-arm, open-label, phase II trial conducted in China, we enrolled patients aged 18\u201380 years with laparoscopically proven gastric cancer and peritoneal metastasis. Patients received toripalimab (3\u00a0mg\/kg) plus FLOT chemotherapy (docetaxel 50 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; oxaliplatin 85 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; leucovorin 200 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 5-FU 2600 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) every 14 days for up to 4 cycles, followed by surgical resection. Patients who underwent surgery subsequently received 4 cycles of adjuvant treatment. The primary endpoint was the R0 resection conversion rate. The secondary endpoints included progression-free survival (PFS), overall survival (OS) and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between April 2021 and April 2023, 24 patients were screened, 20 of whom were included in this analysis. The median follow-up was 10.8 months. The objective response rate (ORR) was 35% and the disease control rate (DCR) was 80%. The R0 resection conversion rate after treatment was 25% (5\/20), 40% (2\/5) participants achieved TRG1 and 60% (3\/5) participants achieved TRG2. The median PFS and OS were 6.5 and 10.8 months, respectively. Grade 3\u20134 treatment-related adverse events (TRAEs) occurred in 35% of participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Toripalimab combined with FLOT chemotherapy demonstrated potential conversion efficacy in the treatment of gastric cancer with peritoneal metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial information<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT04886193). Date of registration: 13 May 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15166-w","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:26:06Z","timestamp":1762597566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Toripalimab combined with FLOT chemotherapy as conversion therapy for gastric cancer with peritoneal metastasis: a single-arm, open-label, phase II trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Zijing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanSheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"3","key":"15166_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15166_CR2","first-page":"1","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1\u20139.","journal-title":"J Natl Cancer Cent"},{"issue":"9","key":"15166_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547\u201353.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15166_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321.","journal-title":"Lancet Oncol"},{"issue":"2","key":"15166_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10120-017-0738-1","volume":"21","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, et al. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2018;21(2):315\u201323.","journal-title":"Gastric Cancer"},{"key":"15166_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/1471-2407-13-577","volume":"13","author":"J Sun","year":"2013","unstructured":"Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:577.","journal-title":"BMC Cancer"},{"issue":"3","key":"15166_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10120-016-0633-1","volume":"20","author":"Y Sato","year":"2017","unstructured":"Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20(3):517\u201326.","journal-title":"Gastric Cancer"},{"issue":"9","key":"15166_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237\u201344.","journal-title":"JAMA Oncol"},{"issue":"3","key":"15166_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.21873\/invivo.12811","volume":"36","author":"Y Kumagai","year":"2022","unstructured":"Kumagai Y, Futoh Y, Miyato H, Ohzawa H, Yamaguchi H, Saito S, et al. Effect of systemic or intraperitoneal administration of Anti-PD-1 antibody for peritoneal metastases from gastric cancer. Vivo. 2022;36(3):1126\u201335.","journal-title":"Vivo"},{"issue":"10294","key":"15166_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"key":"15166_CR11","doi-asserted-by":"crossref","unstructured":"Rationale 305. Phase 3 study of Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC). J Clin Oncol 41:286\u2013286.","DOI":"10.1200\/JCO.2023.41.4_suppl.286"},{"issue":"9","key":"15166_CR12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"F Wang","year":"2019","unstructured":"Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479\u201386.","journal-title":"Ann Oncol"},{"issue":"1","key":"15166_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12957-019-1761-y","volume":"17","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chen JQ, Liu JL, Tian L. Issues on peritoneal metastasis of gastric cancer: an update. World J Surg Oncol. 2019;17(1):215.","journal-title":"World J Surg Oncol"},{"key":"15166_CR14","doi-asserted-by":"publisher","unstructured":"Yu P, Ding G, Huang X, Wang C, Fang J, Huang L et al. Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study. Int J Surg. 2024 Jun 1;110(6):3504-3517. https:\/\/doi.org\/10.1097\/JS9.0000000000001281","DOI":"10.1097\/JS9.0000000000001281"},{"issue":"4","key":"15166_CR15","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/cam4.5277","volume":"12","author":"L Tu","year":"2023","unstructured":"Tu L, Zhang W, Ni L, Xu Z, Yang K, Gou H, et al. Study of SOX combined with intraperitoneal high-dose Paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial. Cancer Med. 2023;12(4):4161\u20139.","journal-title":"Cancer Med"},{"issue":"1","key":"15166_CR16","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1186\/s12885-021-09027-5","volume":"21","author":"M Shi","year":"2021","unstructured":"Shi M, Yang Z, Lu S, Liu W, Ni Z, Yao X, et al. Oxaliplatin plus S-1 with intraperitoneal Paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. BMC Cancer. 2021;21(1):1344.","journal-title":"BMC Cancer"},{"issue":"2","key":"15166_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358\u201363.","journal-title":"Cancer"},{"issue":"3","key":"15166_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622\u20138.","journal-title":"Int J Cancer"},{"issue":"12","key":"15166_CR19","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","volume":"22","author":"I Chau","year":"2004","unstructured":"Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2013pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22(12):2395\u2013403.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15166_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/jcm13030834","volume":"13","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Ando T, Takahashi N, Tsukada K, Takagi H, Goto Y, et al. The efficacy and safety of nivolumab plus mFOLFOX6 in gastric cancer with severe peritoneal metastasis. J Clin Med. 2024;13(3):834.","journal-title":"J Clin Med"},{"issue":"2","key":"15166_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10120-023-01452-8","volume":"27","author":"Z Yang","year":"2024","unstructured":"Yang Z, Lu S, Shi M, Yuan H, Wang Z, Ni Z, et al. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study. Gastric Cancer. 2024;27(2):387\u201399.","journal-title":"Gastric Cancer"},{"issue":"11","key":"15166_CR22","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","volume":"19","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the arbeitsgemeinschaft internistische onkologie. Ann Oncol. 2008;19(11):1882\u20137.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15166-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15166-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15166-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:52:36Z","timestamp":1781614356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15166-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15166"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15166-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BF2021-065-01). The study was executed in accordance with the ethical standards set forth in the Declaration of Helsinki, Good Clinical Practice guidelines and local regulatory requirements. Written informed consent was obtained from all participants prior to their inclusion in the study. The trial is registered on ClinicalTrials.gov (NCT04886193).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1733"}}